Oliveira Claudia P M S, Alves Venâncio A F, Lima Vicência M R, Stefano José Tadeu, Debbas Victor, Sá Sandra Valéria, Wakamatsu Alda, Corrêa-Giannella Maria Lúcia, de Mello Evandro Sobroza, Havaki Sofia, Tiniakos Dina G, Marinos Evangelos, de Oliveira Marcelo G, Giannella-Neto Daniel, Laurindo Francisco R, Caldwell Stephen, Carrilho Flair J
Department of Gastroenterology, University of São Paulo School of Medicine, Brazil.
Biochem Pharmacol. 2007 Jul 15;74(2):290-7. doi: 10.1016/j.bcp.2007.04.013. Epub 2007 Apr 21.
We evaluated the effects of a potent NO donor, S-nitroso-N-acetylcysteine (SNAC), on microsomal triglyceride transfer protein (MTP) expression in ob/ob mice. NAFLD was induced in male ob/ob mice using a methionine-choline deficient diet (MCD) concomitantly with oral SNAC fed solution (n=5) or vehicle (control; n=5) by gavage daily for 4 weeks. Livers were collected for histology and for assessing MTP by RT-qPCR, Western blot, immunohistochemistry and immunogold electron microscopy analyses. Histological analysis showed diffuse macro and microvesicular steatosis, moderate hepatocellular ballooning and moderate inflammatory infiltrate in ob/ob mice fed the MCD diet. With SNAC, mice showed a marked reduction in liver steatosis (p<0.01), in parenchymal inflammation (p=0.02) and in MTP protein immunoexpression in zone III (p=0.05). Moreover, SNAC caused reduction of MTP protein in Western blot analysis (p<0.05). In contrast, MTP mRNA content was significantly higher (p<0.05) in mice receiving SNAC. Immuno-electron microscopy showed MTP localized in the rough endoplasmic reticulum of hepatocytes in both treated and untreated groups. However with SNAC treatment, MTP was also observed surrounding fat globules. Histological improvement mediated by a nitric oxide donor is associated with significantly altered expression and distribution of MTP in this animal model of fatty liver disease. Further studies are in progress to examine possible mechanisms and to develop SNAC as a possible therapy for human fatty liver disease.
我们评估了一种强效一氧化氮供体S-亚硝基-N-乙酰半胱氨酸(SNAC)对ob/ob小鼠微粒体甘油三酯转运蛋白(MTP)表达的影响。使用蛋氨酸-胆碱缺乏饮食(MCD)诱导雄性ob/ob小鼠发生非酒精性脂肪性肝病(NAFLD),同时每天通过灌胃给予口服SNAC喂养溶液(n = 5)或赋形剂(对照组;n = 5),持续4周。收集肝脏用于组织学检查,并通过逆转录定量聚合酶链反应(RT-qPCR)、蛋白质免疫印迹法、免疫组织化学和免疫金电子显微镜分析来评估MTP。组织学分析显示,喂食MCD饮食的ob/ob小鼠出现弥漫性大泡性和小泡性脂肪变性、中度肝细胞气球样变和中度炎症浸润。给予SNAC后,小鼠肝脏脂肪变性(p<0.01)、实质炎症(p = 0.02)和Ⅲ区MTP蛋白免疫表达(p = 0.05)均显著降低。此外,蛋白质免疫印迹分析显示SNAC导致MTP蛋白减少(p<0.05)。相比之下,接受SNAC的小鼠中MTP mRNA含量显著更高(p<0.05)。免疫电子显微镜显示,在治疗组和未治疗组中,MTP均定位于肝细胞的粗面内质网。然而,在SNAC治疗组中,还观察到MTP围绕脂肪球分布。在该脂肪肝疾病动物模型中,一氧化氮供体介导的组织学改善与MTP表达和分布的显著改变有关。目前正在进行进一步研究,以探讨可能的机制,并将SNAC开发为治疗人类脂肪肝疾病的一种可能疗法。